South America, the Middle East and Asia Pacific are the regions of the globe where the markets for drugs to treat skin conditions are growing most rapidly. The markets in these regions will increase by 28% on average in the five years 2016 to 2020, according to forecasts by TBRC. In contrast the markets in North America and Western Europe will grow by only 9% on average over the same period.

One of the fast-growing markets for sales of dermatology drugs, Asia Pacific, is about the same size as North America’s, the world’s largest; the others are smaller. The global market for dermatology drugs itself is a comparatively small one, representing 3.5% of the global market for pharma as a whole.

The relatively rapid growth of sales for these drugs in the three fast-growing regions is partly explained by the presence of large populations in tropical or subtropical regions where dermatological disease incidence is high. Another factor is the sale of many of these drugs without prescription so that limited access to medical services does not hold back the market, especially as the populations urbanise. In some countries of these regions rapid growth of GDP per capita is also a factor in high market growth. These factors make these regions present good opportunities to manufacturers of drugs used to treat skin conditions.

The leading competitor in the global market for dermatology drugs is the USA’s Johnson & Johnson, closely followed by Allergan, which is headquarted in Dublin, Eire, and Galderma, with its headquarters in Lausanne, Switzerland. These three companies share about a third of the market between them. Nearly 50% is split among a large number of small pharma businesses.

One of the trends which is shaping the market is an increase in number of mergers and acquisitions in the dermatology drugs market. The dermatology drugs market has witnessed multiple strategic initiatives in the recent years. Top companies in the dermatology drugs market strategically acquired start-ups and mid-sized companies to broaden products and services. For instance, LEO Pharma, a Denmark-based company acquired the global dermatology business of Astellas Pharma for $725 million. This deal allows LEO to increase its product portfolio with Astellas Pharma’s dermatology products including Protopic, Locoid, Locobase and Zineryt. Also Piramal Enterprises Ltd, an Indian based company acquired over-the-counter dermatology brand Caladryl in India from Valeant Pharmaceuticals Inc. Through this acquisition Piramal widened its consumer products portfolio in the skin care segment.

Where to Learn More
Read Dermatology Drugs Global Market Report 2018 from The Business Research Company for information on the following:

The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained researchers in 15 countries globally.